BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus® and Lantus® SoloStar®
Paris, France - October 24, 2017 - Sanofi (EURONEXT: SAN and NYSE: SNY) today filed a patent infringement suit against Mylan N.V., Mylan GmbH, Mylan Inc., and Mylan Pharmaceuticals Inc. (collectively, "Mylan") in the United States District Court for the District of New Jersey. Sanofi alleges infringement of 18 patents in its suit.
The suit was triggered by notifications received from Mylan beginning in mid-September, in which Mylan stated that it had filed a NDA (505(b)(2) New Drug Application) with the FDA for insulin glargine pre-filled pen and vial drug products. Mylan also stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for Sanofi's Lantus® (insulin glargine injection, 100 Units/mL) and Lantus® SoloStar® products.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Contacts:
| Media Relations Ashleigh Koss Tel. : +1 (908) 981-8745 Mobile: +1 (908) 205-2572 [email protected] | Investor Relations George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/1c119d99-fda9-450b-914a-8f21711204a3
